Nineteen insiders at ADARx Pharmaceuticals, Inc. (ADRX) executed significant share purchases on September 30, 2026, collectively acquiring approximately $97.95 million worth of stock. The transactions saw multiple entities affiliated with Orbimed Advisors, including Advisors Llc Orbimed, Israel Gp Ii, L.P. Orbimed, Advisors Israel Ii Ltd Orbimed, Capital Gp Vii Llc Orbimed, and Genesis Gp Llc Orbimed, each purchase substantial blocks of shares. Director Carl L. Gordon and Director Erez Chimovits also participated in these buys.
The purchases were made at a uniform price of $17.00 per share. This cluster insider buying, where numerous company insiders purchase shares within a short period, is often viewed as a strong bullish indicator for the stock.
The collective investment by these key figures suggests a heightened confidence in the company's future prospects and underlying valuation.